Hotelbuchung
Hotel Registration
Grußwort
Welcome address
Beteiligte Gesellschaften
Societies involved
DOG Information
DOG Information
Eröffnung des Kongresses
Opening Ceremony
Preise
Awards
Ablauf der Tagung 2003
General overview of congress
Lageplan der Räumlichkeiten
Map of Congress Center
Wissenschaftliche Themen
Scientific topics
Symposien
Symposia
Wissenschaftliches Programm
Scientific program
Posterpräsentationen
Poster Presentation
Kurse
Courses
Begleitende Veranstaltungen
Accompanying program
Arbeitssitzungen
Working sessions
Rahmenprogramm
Social program
Allgemeine Informationen
General Information
Autorenindex
Index of Authors
Industrieaussteller
Commercial exhibitors
Sponsoren
Sponsors
Impressum
DOG Homepage
Abstract
Abstract
ILM Peeling versus Triamcinolone in Persistent Diabetic Macular Edema (TIME-Study)
Joussen A. M.1, Kirchhof B.1, Wolf S.2, Hilgers R.-D.3
1Universität zu Köln, Zentrum für Augenheilkunde, Abteilung für Netzhaut- und Glaskörperchirurgie, Köln; 2Universität Leipzig, Klinik und Poliklinik für Augenheilkunde, Leipzig; 3RWTH Aachen, Institut für Medizinische Statistik, Aachen
Aim: Improvement of the visual outcome for patients with persistent diabetic macular edema
Study Design: Three arm parallel group design: two treatment groups, and one control group
Patients: Patients with persistent macular edema (as a consequence of diabetic maculopathy)
Time of the Study: 4 years
Treatment:
· Group 1: control: no treatment
· Group 2: ppV and posterior vitreous detachment + ILM peeling
· Group 3: triamcinolone 4 mg (6 monthly (optional))
Inclusion Criteria:
· Persistent (diffuse or focal) macular edema (more than 6 month) as demonstrated by fluorescein angiography according to ETDRS criteria for CSME associated with diabetes
· BCVA of the treatment eye £20/50 +3 £ETDRS letters) and ³20/320 (³25 ETDRS letters). Fellow eye ³20/100 (25 ETDRS letters)
· Last focal or grid laser treatment for macular edema more than 3 month prior to treatment
· Type II diabetes
Zurück | Back